2 completed, 1 recruiting, 1 unknown. 3 Phase 4, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 3 | Completed 1, Recruiting 1, Unknown 1 |
| Not applicable | 1 | Completed 1 |
Follow Signe Torekov: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| FutureShape Family Family Care, Standard Care, Semaglutide (administered by PDS290 pen-injector) - Obesity, Overweight | Phase 4 | Recruiting | Signe Torekov | 400 | 2026-10-01 | 2026-10-29 |
| Young Adults With Early-onset Obesity Treated With Semaglutide TCOC treatment, Semaglutide 3 mg/ml, Placebo (Semaglutide 3 mg/ml) - Obesity, Adolescent | Phase 4 | Completed | Signe Torekov | 246 | 2022-05-30 | 2026-07-08 |
| The Physiological Effects of Human Ether-a-go-go-Related Gene (hERG)Blockade on Metabolism Moxifloxacin, Placebo - Long QT Syndrome, Hypoglycemia | Not applicable | Completed | Signe Torekov | 44 | 2019-01-28 | 2022-04-14 |
| Combined Effects of GLP-1 Analogue and Exercise on Maintenance of Weight Loss and Health After Very-low Calorie Diet Liraglutide, Exercise - Obesity | Phase 4 | Unknown | Signe Torekov | 215 | 2016-09-01 | 2020-11-02 |
Obesity (2) · Hypoglycemia (1) · Long QT Syndrome (1) · Motor Activity (1) · Overweight (1) · Pediatric Obesity (1) · Weight Loss (1)
semaglutide (2) · Exercise (1) · Liraglutide (1) · Moxifloxacin (1) · Standard of Care (1)
Denmark (4)
Signe S Torekov, Prof, PhD (2) · Jens-Christian Holm, Ass. Prof, PhD (1) · Signe S. Torekov, MSc, PhD (1) · Sten Madsbad, Prof, MD (1)
PMID 33951361, PMID 35580859, PMID 35970829, PMID 36472579, PMID 36841762, PMID 38544798, PMID 39530599, PMID 40998556, PMID 41579235, PMID 42342869
2015 (1), 2019 (1)